XML 23 R13.htm IDEA: XBRL DOCUMENT
v3.23.2

Shareholders' Equity | 6 Months Ended
--- | ---
Jun. 30, 2023
Shareholders' Equity |
Shareholders' Equity | 7. Shareholders’ Equity (a)Authorized shares The Company is authorized to issue an unlimited number of Common Shares with no par value and an unlimited number of Preferred Shares with no par value. (b)Purchases of Equity Shares Normal Course Issuer Bid On March 9, 2023, the Board of Directors authorized a new share repurchase program of up to 2,292,644 common shares, representing 10% of the outstanding common shares of Epsilon, for an aggregate purchase price of not more than US $15.0 million. The program is pursuant to a normal course issuer bid and will be conducted in accordance with Rule 10b-18 under the Exchange Act. The program commenced on March 27, 2023 and will end on March 26, 2024, unless the maximum amount of common shares is purchased before then or Epsilon provides earlier notice of termination. During the six months ended June 30, 2023, we repurchased 372,275 common shares at an average price of $5.19 per share (excluding commissions) under the new plan. The previous share repurchase program commenced on March 8, 2022. During the year ended December 31, 2022, we repurchased 982,500 common shares of the maximum of 1,183,410 authorized for repurchase and spent $6,234,879 under the plan. The repurchased stock had an average price of $6.32 per share (excluding commissions) and was subsequently retired during the year ended December 31, 2022. In 2023, we repurchased and retired 190,700 common shares at an average price of $5.82 per share (excluding commissions) before the plan terminated on March 7, 2023. During the six months ended June 30, 2023, the Company repurchased 562,975 shares at an average price of $5.40 per share (excluding commissions) under the two consecutive repurchase programs. The following table contains activity relating to our acquisition of equity securities during the six months ended June 30, 2023:
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ |  | ​ | ​ | Maximum number
​ | ​ | ​ | ​ | ​ | ​ | of shares
​ | ​ | Total number | ​ | Average price | ​ | remaining to be
​ | ​ | of shares | ​ | paid per | ​ | purchased under
​ |  | purchased | ​ | share |  | the program
Beginning of normal-course issuer bid, March 8, 2022 (1) | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 1,183,410
January 2023 | ​ | 125,200 | ​ | $ | 5.96 | ​ | ​ | ​
February 2023 | ​ | 65,500 | ​ | $ | 5.63 | ​ | ​ | ​
Total as of March 7, 2023 | ​ | 190,700 | ​ | $ | 5.82 | ​ | ​ | 10,210
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Beginning of normal-course issuer bid, March 27, 2023 (2) | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 2,292,644
March 2023 | ​ | 47,220 | ​ | $ | 5.32 | ​ | ​ | ​
April 2023 | ​ | 70,406 | ​ | $ | 5.35 | ​ | ​ | ​
May 2023 | ​ | 83,097 | ​ | $ | 5.11 | ​ | ​ | ​
June 2023 | ​ | 171,552 | ​ | $ | 5.13 | ​ | ​ | ​
Total as of June 30, 2023 | ​ | 372,275 | ​ | $ | 5.11 | ​ | ​ | 1,920,369
| (1) | Epsilon repurchased these shares under its 2022-2023 share repurchase program that commenced on March 8, 2022 and terminated on March 7, 2023, as described above.
| (2) | Epsilon repurchased these shares under its 2023-2024 share repurchase program that commenced on March 27, 2023, as described above.
(c)Equity Incentive Plan Epsilon’s board of directors (the “Board”) adopted the 2020 Equity Incentive Plan (the “2020 Plan”) on July 22, 2020 subject to approval by Epsilon’s shareholders at Epsilon’s 2020 Annual General and Special Meeting of Shareholders, which occurred on September 1, 2020 (the “Meeting”). Shareholders approved the 2020 Plan at the Meeting. Following Epsilon’s listing on the NASDAQ Global Market, the Board had determined that it was in the best interest of the shareholders to approve a new incentive plan that is compliant with U.S. public company equity plan rules and practices that would replace Epsilon’s Amended and Restated 2017 Stock Option Plan (including its predecessors) and the Share Compensation Plan (collectively referred to as the “Predecessor Plans”). No further awards will be granted under the Predecessor Plans. The 2020 Plan provides for incentive compensation in the form of stock options, stock appreciation rights, restricted stock and stock units, performance shares and units, other stock-based awards and cash-based awards. Under the 2020 Plan, Epsilon will be authorized to issue up to 2,000,000 Common Shares. Restricted Stock Awards For the six months ended June 30, 2023, no shares of Restricted Stock were awarded to the Company’s board of directors and employees. For the year ended December 31, 2022, 289,231 common shares of Restricted Stock with a weighted average market price at the grant date of $6.28 were awarded to the Company’s officers, employees, and board of directors. These shares vest over a three or four-year period, with an equal number of shares being issued per period on the anniversary of the award resolution. The vesting of the shares is contingent on the individuals’ continued employment or service. The Company determined the fair value of the granted Restricted Stock-based on the market price of the common shares of the Company on the date of grant. The following table summarizes Restricted Stock activity for the six months ended June 30, 2023, and the year ended December 31, 2022: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Six months ended | ​ | Year ended
​ | ​ | June 30, 2023 | ​ | December 31, 2022
​ | ​ | Number of | ​ | Weighted | ​ | Number of | ​ | Weighted
​ | ​ | Restricted | ​ | Average | ​ | Restricted | ​ | Average
​ | ​ | Shares | ​ | Remaining Life | ​ | Shares | ​ | Remaining Life
​ |  | Outstanding |  | (years) |  | Outstanding |  | (years)
Balance non-vested Restricted Stock at beginning of period | ​ | 298,210 | ​ | 1.74 | ​ | 166,002 | ​ | 1.38
Granted | ​ | — | ​ | — | ​ | 289,231 | ​ | 1.86
Vested | ​ | — | ​ | — | ​ | (157,023) | ​ | —
Balance non-vested Restricted Stock at end of period | ​ | 298,210 | ​ | 1.24 | ​ | 298,210 | ​ | 1.74
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ Stock compensation expense for the granted Restricted Stock is recognized over the vesting period. Stock compensation expense recognized during the three and six months ended June 30, 2023 was $165,064 and $330,128, respectively (for the three and six months ended June 30, 2022, $146,860 and $241,972, respectively). At June 30, 2023, the Company had unrecognized stock-based compensation related to these shares of $1,338,437 to be recognized over a weighted average period of 1.34 years (at December 31, 2022: $1,668,564 over 1.55 years). Performance Share Unit Awards (“PSU”) For the six months ended June 30, 2023, no PSUs vested and were issued. For the year ended December 31, 2022, a total of 135,667 common shares vested and were issued. Previously granted PSUs will vest on the last day of the performance period. The number of PSUs that will ultimately vest is based on two performance targets as follows:
| ● | The targets for the PSUs are based on (i) the relative total stockholder return (“TSR”) percentile ranking and (ii) the relative cash flow per debt adjusted share – growth (“CFDAS Growth”) percentile ranking of the Company, each as compared to the Company’s Performance Peer Group during the applicable one-year performance period ending on December 31.
| ● | Cash Flow per Debt Adjusted Share (“CFDAS”) is defined as EBITDA (earnings before interest, taxes, depreciation and amortization) divided by the sum of the 1) the total debt plus the value of preferred stock minus cash and the amount of dividends paid for the year divided by the share price at the end of the year; and 2) the actual share count at year end.
| ● | The vesting of each PSU Award will be based 50% on TSR performance and 50% based on CFDAS Growth performance.
| ● | The recipient of the award must be employed with the Company at the time of vesting.
The number of shares ultimately issued under these awards can range from zero to 200% of target award amounts at the discretion of the Compensation Committee of the Board of Directors. The following table summarizes PSUs for the six months ended June 30, 2023 and the year ended December 31, 2022: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Six months ended | ​ | Year ended
​ | ​ | June 30, 2023 | ​ | December 31, 2022
​ | ​ | Number of | ​ | Weighted | ​ | Number of | ​ | Weighted
​ | ​ | Performance | ​ | Average | ​ | Performance | ​ | Average
​ | ​ | Shares | ​ | Remaining Life | ​ | Shares | ​ | Remaining Life
​ |  | Outstanding |  | (years) |  | Outstanding |  | (years)
Balance non-vested PSUs at beginning of period | ​ | 15,833 | ​ | 1.00 | ​ | 151,500 | ​ | 3.84
Vested | ​ | — | ​ | — | ​ | (135,667) | ​ | —
Balance non-vested PSUs at end of period | ​ | 15,833 | ​ | 0.50 | ​ | 15,833 | ​ | 1.00
​ Stock compensation expense for the granted PSUs is recognized over the vesting period. Stock compensation expense recognized during the three and six months ended June 30, 2023 related to PSUs was $14,684 and $29,368, respectively (for the three and six months ended June 30, 2022, $47,190 and $94,380, respectively). At June 30, 2023, the Company had unrecognized stock-based compensation related to these shares of $29,368 to be recognized over a weighted average period of 0.38 years (at December 31, 2022: $63,328 over 0.63 years). ​ Stock Options As of June 30, 2023, the Company had outstanding stock options covering 70,000 Common Shares at an overall average exercise price of $5.03 per Common Share to directors, officers, and employees of the Company and its subsidiaries. These 70,000 options have a weighted average expected remaining term of approximately 0.55 years. The following table summarizes stock option activity for the six months ended June 30, 2023 and the year ended December 31, 2022: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Six months ended | ​ | Year ended
​ | ​ | June 30, 2023 | ​ | December 31, 2022
​ | ​ | ​ | ​ | Weighted | ​ | ​ | ​ | Weighted
​ | ​ | Number of | ​ | Average | ​ | Number of | ​ | Average
​ | ​ | Options | ​ | Exercise | ​ | Options | ​ | Exercise
Exercise price in US$ |  | Outstanding |  | Price |  | Outstanding |  | Price (1)
Balance at beginning of period | ​ | 70,000 | ​ | $ | 5.03 | ​ | ​ | 218,750 | ​ | $ | 5.28
Exercised | ​ | — | ​ | $ | — | ​ | ​ | (138,750) | ​ | $ | 5.38
Expired/Forfeited | ​ | — | ​ | $ | — | ​ | ​ | (10,000) | ​ | $ | 5.51
Balance at period-end | ​ | 70,000 | ​ | $ | 5.03 | ​ | ​ | 70,000 | ​ | $ | 5.03
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Exercisable at period-end | ​ | 70,000 | ​ | $ | 5.03 | ​ | ​ | 70,000 | ​ | $ | 5.03
​ At June 30, 2023, the Company had unrecognized stock-based compensation, related to these options, of nil (at December 31, 2022: nil). The aggregate intrinsic value at June 30, 2023 was $21,700 (at December 31, 2022: $112,000). During the six months ended June 30, 2023 and the year ended December 31, 2022, the Company awarded no stock options. ​ (d) Dividends ​ On March 3, 2023 and June 6, 2023, the Board declared quarterly dividends of $0.0625 per common share (annualized $0.25 per common share) totaling in aggregate an amount of approximately $2.8 million that has been paid for the six months ended June 30, 2023.

X
- References No definition available. + Details
Name: | us-gaap_EquityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -URI https://asc.fasb.org/topic&trid=2208762 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI https://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration